Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

DOI Full Paper Access

162

Citations

17

References

2021

Year

Séverine Vermeire, Geert D’Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V. Loftus, Siddharth Bhatia, Christian Agboton, Maria Rosario, Chunlin Chen,

Journal of Crohn s and Colitis

Abstract

Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.

References

	Year	Citations

Page 1